Company intelligence / Profile preview
Gavia BIO
Minneapolis/St. Paul area*, Minnesota, United Statesgavia-bio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Gavia BIO develops a novel antimicrobial peptide and hydrogel formulation aimed at treating chronic wounds, burns, and oral infections by targeting resistant bacterial pathogens. The company’s lead technology has not yet reached clinical trials but addresses significant unmet needs in combating antibiotic resistance. No published clinical results as of mid/late 2024.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Antimicrobial peptides (AMPs)hydrogel-based therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Not specified; likely academic partnership with University of Minnesota based on founder affiliation and university startup status.
Beyond the preview
Go deeper on Gavia BIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gavia BIO.